# Albert David (NSE: ALBERTDAVD) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ALBERTDAVD · Pivot · prices to 22 Oct 2026

Albert David (NSE: ALBERTDAVD) closed at ₹761.00 on 22 Oct 2026, down 0.60% on the day. With a market capitalisation of ₹434 Cr, it ranks 1861st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 4.4% in FY25. Over the past year the share price has fallen 3.4%. Its 52-week range is ₹579.90 (30 Mar 2026) to ₹931.85 (31 Aug 2026); the last close is 18.3% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹101 Cr (+43.6% year on year) and net profit ₹32 Cr (+303.0%), on a standalone basis. Promoters held 62.24% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹761.00 |
| Market cap | ₹434 Cr |
| ROE | 4.4% (FY25) |
| ROCE | 6.3% (FY25) |
| Debt to equity | 0.03 |
| 52-week high | ₹931.85 (31 Aug 2026) |
| 52-week low | ₹579.90 (30 Mar 2026) |
| 1-year return | −3.4% |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹101 Cr | +43.6% | ₹32 Cr | +303.0% | ₹56.07 |
| Q4 FY26 | ₹86 Cr | +14.6% | −₹21 Cr | — | −₹37.56 |
| Q3 FY26 | ₹90 Cr | +8.2% | ₹15 Cr | — | ₹26.81 |
| Q2 FY26 | ₹87 Cr | −11.4% | −₹3 Cr | −118.3% | −₹5.79 |
| Q1 FY26 | ₹71 Cr | −21.0% | ₹8 Cr | −57.9% | ₹13.91 |
| Q4 FY25 | ₹75 Cr | −15.9% | −₹10 Cr | −180.0% | −₹18.10 |
| Q3 FY25 | ₹83 Cr | −5.9% | −₹9 Cr | −150.2% | −₹16.45 |
| Q2 FY25 | ₹98 Cr | +5.6% | ₹18 Cr | −11.0% | ₹31.67 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹346 Cr | ₹17 Cr |
| FY24 | ₹362 Cr | ₹75 Cr |
| FY23 | ₹342 Cr | ₹36 Cr |
| FY22 | ₹314 Cr | ₹35 Cr |
| FY21 | ₹247 Cr | ₹22 Cr |
| FY20 | ₹321 Cr | ₹19 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 62.24%
- Foreign institutions: 0.57%
- Domestic institutions: 1.64%
- Non-institutions: 35.56%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [HALEOS LABS](https://app.pivotnow.in/stock/HALEOSLABS) | ₹1,604.40 | ₹485 Cr | 28 | — |
| [Prevest Denpro](https://app.pivotnow.in/stock/PREVEST) | — | ₹472 Cr | — | — |
| [Asarfi Hospital](https://app.pivotnow.in/stock/ASARFI) | — | ₹446 Cr | — | — |
| [Jenburkt Pharma](https://app.pivotnow.in/stock/JENBURPH) | ₹898.80 | ₹397 Cr | 11.4 | — |
| [Transchem](https://app.pivotnow.in/stock/TRANSCHEM) | — | ₹391 Cr | — | — |
| [Aptus Pharma](https://app.pivotnow.in/stock/APPL) | — | ₹377 Cr | — | — |

## Questions and answers

### What is the share price of Albert David today?

Albert David (NSE: ALBERTDAVD) last closed at ₹761.00 on 22 Oct 2026. Its 52-week high is ₹931.85 and its 52-week low is ₹579.90.

### What is the market cap of Albert David?

Albert David's market capitalisation is ₹434 Cr (₹434 Cr) at the 22 Oct 2026 close, ranking 1861st among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Albert David?

Return on equity was 4.4% in FY25 and return on capital employed was 6.3% in FY25 (standalone figures).

### Is Albert David a debt-free company?

Albert David is close to debt-free: its debt-to-equity ratio was 0.03 in FY25.

### What were Albert David's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Albert David reported revenue of ₹101 Cr, +43.6% year on year, and net profit of ₹32 Cr, +303.0% year on year.

### How has Albert David stock performed over the last year?

Albert David's share price has fallen 3.4% over the past year, +10.8% over three months and −9.9% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Albert David?

As of 30 Jun 2026: promoters 62.24%, foreign institutions 0.57%, domestic institutions 1.64%, non-institutions 35.56%.

### Who are Albert David's competitors?

The listed Pharma & Healthcare companies closest to Albert David by market cap are HALEOS LABS, Prevest Denpro, Asarfi Hospital, Jenburkt Pharma, Transchem and Aptus Pharma.

### Is Albert David a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Albert David's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ALBERTDAVD against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.